EZH2 Inhibitor Cuts Risk of Progression in Metastatic Prostate Cancer | MedPage Today
Unlocking the Secrets of Mevrometostat in mCRPC Treatment Michael Schweizer, MD, Fred Hutchinson Cancer Center, Seattle, WA, comments on findings from a Phase I study (NCT03460977) on mevrometostat , an EZH2 inhibitor, plus enzalutamide in metastatic castration-resistant prostate cancer (mCRPC). Mevrometostat showed dose-dependent EZH2 inhibition, reducing key pharmacodynamic markers and altering tumor gene expression. Tumor suppressor genes were reactivated, while genes involved in tumor progression were suppressed. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA. As a renowned oncology expert, Dr. Schweizer delves into the intricacies of biomarker translational studies, specifically focusing on mevrometostat and enzalutamide in treating metastatic castration-resistant prostate cancer (mCRPC). Their research has far-reaching implications for improving treatment outcomes The study built upon the success of phase one trials combining mev...